RVT-101

In a report published Thursday, Chardan Capital Markets analyst Gbola Amusa commented on Axovant Sciences Ltd (NYSE: AXON) following the company's completer analysis from a previously-published phase IIb which were "less robust scientifically" and "less relevant to the...